{"nctId":"NCT00915525","briefTitle":"Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence","startDateStruct":{"date":"2010-02-01","type":"ACTUAL"},"conditions":["Overactive Bladder","Urinary Incontinence"],"count":829,"armGroups":[{"label":"botulinum toxin Type A 100U","type":"EXPERIMENTAL","interventionNames":["Biological: botulinum toxin Type A"]},{"label":"botulinum toxin Type A 150U","type":"EXPERIMENTAL","interventionNames":["Biological: botulinum toxin Type A"]}],"interventions":[{"name":"botulinum toxin Type A","otherNames":["BOTOXÂ®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participation in preceding study 191622-095 (NCT00910845) or 191622-520 (NCT00910520)\n\nExclusion Criteria:\n\n* Females who are pregnant, nursing or planning a pregnancy\n* Patient has any condition or situation which, in the Investigators opinion, would put the patient at risk from continuing treatment with botulinum toxin Type A","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes","description":"Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of incontinence episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in incontinence episodes (improvement) and a positive number change from baseline indicates an increase in the number of incontinence episodes (worsening).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.55","spread":"3.617"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.26","spread":"3.439"}]}]}]},{"type":"PRIMARY","title":"Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes","description":"Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of incontinence episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in incontinence episodes (improvement) and a positive number change from baseline indicates an increase in the number of incontinence episodes (worsening).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.70","spread":"3.685"},{"groupId":"OG001","value":"5.66","spread":"3.798"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.64","spread":"3.402"},{"groupId":"OG001","value":"-3.05","spread":"3.690"}]}]}]},{"type":"PRIMARY","title":"Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes","description":"Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of incontinence episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in incontinence episodes (improvement) and a positive number change from baseline indicates an increase in the number of incontinence episodes (worsening).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.65","spread":"3.380"},{"groupId":"OG001","value":"6.30","spread":"4.280"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.82","spread":"3.341"},{"groupId":"OG001","value":"-3.46","spread":"3.771"}]}]}]},{"type":"PRIMARY","title":"Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes","description":"Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of incontinence episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in incontinence episodes (improvement) and a positive number change from baseline indicates an increase in the number of incontinence episodes (worsening).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.78","spread":"3.463"},{"groupId":"OG001","value":"6.19","spread":"4.140"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.48","spread":"3.733"},{"groupId":"OG001","value":"-3.32","spread":"3.972"}]}]}]},{"type":"PRIMARY","title":"Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes","description":"Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of incontinence episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in incontinence episodes (improvement) and a positive number change from baseline indicates an increase in the number of incontinence episodes (worsening).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.47","spread":"3.283"},{"groupId":"OG001","value":"6.43","spread":"3.622"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.34","spread":"3.791"},{"groupId":"OG001","value":"-3.58","spread":"3.266"}]}]}]},{"type":"PRIMARY","title":"Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes","description":"Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of incontinence episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in incontinence episodes (improvement) and a positive number change from baseline indicates an increase in the number of incontinence episodes (worsening).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.65","spread":"3.238"},{"groupId":"OG001","value":"7.17","spread":"4.223"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.05","spread":"3.493"},{"groupId":"OG001","value":"-3.12","spread":"3.753"}]}]}]},{"type":"PRIMARY","title":"Percentage of Patients With a Positive Response on the 4-Point Treatment Benefit Scale (TBS)","description":"The TBS is a single-item scale in which the patient considers his/her current condition (urinary problems, urinary incontinence) compared with his/her condition before receiving any study treatment in study 191622-095 or 191622-520. Response options are: 1 = greatly improved; 2 = improved; 3 = not changed; and 4 = worsened. Patients scoring either \"greatly improved\" or \"improved\" are considered to have a positive response.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Patients With a Positive Response on the 4-Point TBS","description":"The TBS is a single-item scale in which the patient considers his/her current condition (urinary problems, urinary incontinence) compared with his/her condition before receiving any study treatment in study 191622-095 or 191622-520. Response options are: 1 = greatly improved; 2 = improved; 3 = not changed; and 4 = worsened. Patients scoring either \"greatly improved\" or \"improved\" are considered to have a positive response.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.3","spread":null},{"groupId":"OG001","value":"71.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Patients With a Positive Response on the 4-Point TBS","description":"The TBS is a single-item scale in which the patient considers his/her current condition (urinary problems, urinary incontinence) compared with his/her condition before receiving any study treatment in study 191622-095 or 191622-520. Response options are: 1 = greatly improved; 2 = improved; 3 = not changed; and 4 = worsened. Patients scoring either \"greatly improved\" or \"improved\" are considered to have a positive response.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.1","spread":null},{"groupId":"OG001","value":"71.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Patients With a Positive Response on the 4-Point TBS","description":"The TBS is a single-item scale in which the patient considers his/her current condition (urinary problems, urinary incontinence) compared with his/her condition before receiving any study treatment in study 191622-095 or 191622-520. Response options are: 1 = greatly improved; 2 = improved; 3 = not changed; and 4 = worsened. Patients scoring either \"greatly improved\" or \"improved\" are considered to have a positive response.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.3","spread":null},{"groupId":"OG001","value":"81.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Patients With a Positive Response on the 4-Point TBS","description":"The TBS is a single-item scale in which the patient considers his/her current condition (urinary problems, urinary incontinence) compared with his/her condition before receiving any study treatment in study 191622-095 or 191622-520. Response options are: 1 = greatly improved; 2 = improved; 3 = not changed; and 4 = worsened. Patients scoring either \"greatly improved\" or \"improved\" are considered to have a positive response.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.2","spread":null},{"groupId":"OG001","value":"81.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Patients With a Positive Response on the 4-Point TBS","description":"The TBS is a single-item scale in which the patient considers his/her current condition (urinary problems, urinary incontinence) compared with his/her condition before receiving any study treatment in study 191622-095 or 191622-520. Response options are: 1 = greatly improved; 2 = improved; 3 = not changed; and 4 = worsened. Patients scoring either \"greatly improved\" or \"improved\" are considered to have a positive response.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.9","spread":null},{"groupId":"OG001","value":"81.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in the Daily Average Number of Micturition Episodes","description":"The number of micturition (urination) episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of micturition episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in micturition episodes (improvement) and a positive number change from baseline indicates an increase in the number of micturition episodes (worsening).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.70","spread":"3.584"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.56","spread":"2.887"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in the Daily Average Number of Micturition Episodes","description":"The number of micturition (urination) episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of micturition episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in micturition episodes (improvement) and a positive number change from baseline indicates an increase in the number of micturition episodes (worsening).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.83","spread":"3.634"},{"groupId":"OG001","value":"11.48","spread":"3.912"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.89","spread":"3.037"},{"groupId":"OG001","value":"-2.31","spread":"3.293"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in the Daily Average Number of Micturition Episodes","description":"The number of micturition (urination) episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of micturition episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in micturition episodes (improvement) and a positive number change from baseline indicates an increase in the number of micturition episodes (worsening).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.65","spread":"3.553"},{"groupId":"OG001","value":"12.22","spread":"3.760"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.86","spread":"3.058"},{"groupId":"OG001","value":"-3.01","spread":"3.217"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in the Daily Average Number of Micturition Episodes","description":"The number of micturition (urination) episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of micturition episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in micturition episodes (improvement) and a positive number change from baseline indicates an increase in the number of micturition episodes (worsening).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.68","spread":"3.456"},{"groupId":"OG001","value":"11.82","spread":"3.442"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.69","spread":"3.485"},{"groupId":"OG001","value":"-2.78","spread":"2.882"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in the Daily Average Number of Micturition Episodes","description":"The number of micturition (urination) episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of micturition episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in micturition episodes (improvement) and a positive number change from baseline indicates an increase in the number of micturition episodes (worsening).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.55","spread":"3.261"},{"groupId":"OG001","value":"11.79","spread":"2.770"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.85","spread":"3.181"},{"groupId":"OG001","value":"-3.19","spread":"2.772"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in the Daily Average Number of Micturition Episodes","description":"The number of micturition (urination) episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of micturition episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in micturition episodes (improvement) and a positive number change from baseline indicates an increase in the number of micturition episodes (worsening).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.85","spread":"3.377"},{"groupId":"OG001","value":"11.81","spread":"2.990"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.76","spread":"3.153"},{"groupId":"OG001","value":"-2.66","spread":"3.351"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in the Urinary Incontinence-Specific Quality of Life (I-QOL) Questionnaire Total Summary Score","description":"The I-QOL questionnaire is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure the impact of urinary incontinence on patients' lives. Each question is answered on a 5-point scale (1 = worst QOL and 5 = best QOL). The scores are totaled over the 22 questions and normalized to a score of 0-100 (0 = worst QOL and 100= best QOL). The I-QOL total score is calculated by combining the 22-item subscores from the 3 I-QOL domains: Avoidance Limiting Behavior, Psychological Impact, and Social Embarrassment. The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate improved QOL and negative changes from baseline indicate worsened QOL.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.3","spread":"18.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.0","spread":"24.84"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in the I-QOL Questionnaire Total Summary Score","description":"The I-QOL questionnaire is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure the impact of urinary incontinence on patients' lives. Each question is answered on a 5-point scale (1 = worst QOL and 5 = best QOL). The scores are totaled over the 22 questions and normalized to a score of 0-100 (0 = worst QOL and 100= best QOL). The I-QOL total score is calculated by combining the 22-item subscores from the 3 I-QOL domains: Avoidance Limiting Behavior, Psychological Impact, and Social Embarrassment. The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate improved QOL and negative changes from baseline indicate worsened QOL","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.8","spread":"18.72"},{"groupId":"OG001","value":"32.8","spread":"17.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.6","spread":"24.38"},{"groupId":"OG001","value":"21.6","spread":"23.71"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in the I-QOL Questionnaire Total Summary Score","description":"The I-QOL questionnaire is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure the impact of urinary incontinence on patients' lives. Each question is answered on a 5-point scale (1 = worst QOL and 5 = best QOL). The scores are totaled over the 22 questions and normalized to a score of 0-100 (0 = worst QOL and 100= best QOL). The I-QOL total score is calculated by combining the 22-item subscores from the 3 I-QOL domains: Avoidance Limiting Behavior, Psychological Impact, and Social Embarrassment. The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate improved QOL and negative changes from baseline indicate worsened QOL","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.8","spread":"18.21"},{"groupId":"OG001","value":"31.9","spread":"18.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.6","spread":"22.39"},{"groupId":"OG001","value":"23.7","spread":"25.68"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in the I-QOL Questionnaire Total Summary Score","description":"The I-QOL questionnaire is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure the impact of urinary incontinence on patients' lives. Each question is answered on a 5-point scale (1 = worst QOL and 5 = best QOL). The scores are totaled over the 22 questions and normalized to a score of 0-100 (0 = worst QOL and 100= best QOL). The I-QOL total score is calculated by combining the 22-item subscores from the 3 I-QOL domains: Avoidance Limiting Behavior, Psychological Impact, and Social Embarrassment. The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate improved QOL and negative changes from baseline indicate worsened QOL","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.4","spread":"17.32"},{"groupId":"OG001","value":"32.5","spread":"19.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.3","spread":"24.90"},{"groupId":"OG001","value":"20.3","spread":"22.63"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in the I-QOL Questionnaire Total Summary Score","description":"The I-QOL questionnaire is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure the impact of urinary incontinence on patients' lives. Each question is answered on a 5-point scale (1 = worst QOL and 5 = best QOL). The scores are totaled over the 22 questions and normalized to a score of 0-100 (0 = worst QOL and 100= best QOL). The I-QOL total score is calculated by combining the 22-item subscores from the 3 I-QOL domains: Avoidance Limiting Behavior, Psychological Impact, and Social Embarrassment. The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate improved QOL and negative changes from baseline indicate worsened QOL","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.2","spread":"17.49"},{"groupId":"OG001","value":"31.9","spread":"20.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.1","spread":"23.75"},{"groupId":"OG001","value":"19.5","spread":"21.43"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in the I-QOL Questionnaire Total Summary Score","description":"The I-QOL questionnaire is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure the impact of urinary incontinence on patients' lives. Each question is answered on a 5-point scale (1 = worst QOL and 5 = best QOL). The scores are totaled over the 22 questions and normalized to a score of 0-100 (0 = worst QOL and 100= best QOL). The I-QOL total score is calculated by combining the 22-item subscores from the 3 I-QOL domains: Avoidance Limiting Behavior, Psychological Impact, and Social Embarrassment. The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate improved QOL and negative changes from baseline indicate worsened QOL","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.3","spread":"17.87"},{"groupId":"OG001","value":"30.2","spread":"20.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.6","spread":"24.99"},{"groupId":"OG001","value":"18.3","spread":"14.91"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in the King's Health Questionnaire (KHQ) Role Limitations Domain","description":"The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The role limitations domain consists of 2 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.3","spread":"28.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.5","spread":"34.32"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in the KHQ Role Limitations Domain","description":"The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The role limitations domain consists of 2 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.5","spread":"28.51"},{"groupId":"OG001","value":"66.2","spread":"30.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-32.1","spread":"34.29"},{"groupId":"OG001","value":"-29.2","spread":"35.94"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in the KHQ Role Limitations Domain","description":"The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The role limitations domain consists of 2 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.7","spread":"28.36"},{"groupId":"OG001","value":"63.4","spread":"30.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.7","spread":"33.47"},{"groupId":"OG001","value":"-27.9","spread":"34.57"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in the KHQ Role Limitations Domain","description":"The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The role limitations domain consists of 2 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.3","spread":"27.65"},{"groupId":"OG001","value":"62.3","spread":"31.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.9","spread":"33.82"},{"groupId":"OG001","value":"-23.4","spread":"33.05"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in the KHQ Role Limitations Domain","description":"The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The role limitations domain consists of 2 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.4","spread":"29.15"},{"groupId":"OG001","value":"62.6","spread":"31.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.8","spread":"35.13"},{"groupId":"OG001","value":"-26.3","spread":"28.45"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in the KHQ Role Limitations Domain","description":"The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The role limitations domain consists of 2 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.4","spread":"30.00"},{"groupId":"OG001","value":"60.3","spread":"33.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.8","spread":"38.93"},{"groupId":"OG001","value":"-22.9","spread":"25.64"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in the KHQ Social Limitations Domain","description":"The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The social limitations domain consists of 4 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.1","spread":"30.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.4","spread":"29.46"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in the KHQ Social Limitations Domain","description":"The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The social limitations domain consists of 4 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.0","spread":"30.96"},{"groupId":"OG001","value":"48.4","spread":"30.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.0","spread":"29.12"},{"groupId":"OG001","value":"-19.0","spread":"28.55"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in the KHQ Social Limitations Domain","description":"The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The social limitations domain consists of 4 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.8","spread":"31.02"},{"groupId":"OG001","value":"45.4","spread":"31.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.9","spread":"29.26"},{"groupId":"OG001","value":"-19.2","spread":"28.31"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in the KHQ Social Limitations Domain","description":"The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The social limitations domain consists of 4 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.7","spread":"31.86"},{"groupId":"OG001","value":"43.2","spread":"30.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.8","spread":"31.26"},{"groupId":"OG001","value":"-16.1","spread":"23.17"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in the KHQ Social Limitations Domain","description":"The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The social limitations domain consists of 4 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.4","spread":"31.39"},{"groupId":"OG001","value":"43.4","spread":"32.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.7","spread":"28.47"},{"groupId":"OG001","value":"-15.7","spread":"24.52"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in the KHQ Social Limitations Domain","description":"The KHQ is a disease-specific health-related QOL questionnaire that measures urinary incontinence. The social limitations domain consists of 4 questions answered on a 4-point scale (not at all, slightly, moderate, a lot). The initial study baseline is obtained from data collected prior to the first treatment in Study 191622-095 or 191622-520. Positive number changes from baseline indicate a worsening in role limitations and negative number changes from baseline indicate an improvement in role limitations.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.7","spread":"32.72"},{"groupId":"OG001","value":"43.3","spread":"32.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.0","spread":"33.59"},{"groupId":"OG001","value":"-17.6","spread":"24.43"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in Daily Frequency of Urgency Episodes","description":"The number of urgency episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of urgency episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in urgency episodes (improvement) and a positive number change from baseline indicates an increase in the number of urgency episodes (worsening).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.55","spread":"4.206"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.81","spread":"4.031"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in Daily Frequency of Urgency Episodes","description":"The number of urgency episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of urgency episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in urgency episodes (improvement) and a positive number change from baseline indicates an increase in the number of urgency episodes (worsening).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.63","spread":"4.188"},{"groupId":"OG001","value":"9.09","spread":"4.764"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.07","spread":"4.046"},{"groupId":"OG001","value":"-3.96","spread":"4.519"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in Daily Frequency of Urgency Episodes","description":"The number of urgency episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of urgency episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in urgency episodes (improvement) and a positive number change from baseline indicates an increase in the number of urgency episodes (worsening).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.62","spread":"4.055"},{"groupId":"OG001","value":"9.28","spread":"4.552"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.22","spread":"4.120"},{"groupId":"OG001","value":"-3.86","spread":"4.332"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in Daily Frequency of Urgency Episodes","description":"The number of urgency episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of urgency episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in urgency episodes (improvement) and a positive number change from baseline indicates an increase in the number of urgency episodes (worsening).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.65","spread":"3.951"},{"groupId":"OG001","value":"8.98","spread":"4.241"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.92","spread":"4.341"},{"groupId":"OG001","value":"-3.50","spread":"3.916"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in Daily Frequency of Urgency Episodes","description":"The number of urgency episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of urgency episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in urgency episodes (improvement) and a positive number change from baseline indicates an increase in the number of urgency episodes (worsening).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.67","spread":"3.961"},{"groupId":"OG001","value":"8.89","spread":"3.341"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.11","spread":"4.549"},{"groupId":"OG001","value":"-3.56","spread":"3.576"}]}]}]},{"type":"SECONDARY","title":"Change From Study Baseline in Daily Frequency of Urgency Episodes","description":"The number of urgency episodes are recorded in a patient bladder diary in the 3 consecutive days prior to each study visit for study 191622-096 (or 3 days prior to each visit in study 191622-095 or 191622-520). The number of urgency episodes are averaged daily during this period. The initial study baseline is obtained from the patient bladder diary in the 3 consecutive days prior to the first treatment in either study 191622-095 or 191622-520. A negative number change from baseline indicates a reduction in urgency episodes (improvement) and a positive number change from baseline indicates an increase in the number of urgency episodes (worsening).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.98","spread":"4.059"},{"groupId":"OG001","value":"8.84","spread":"3.629"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.95","spread":"4.662"},{"groupId":"OG001","value":"-2.64","spread":"4.112"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":71,"n":829},"commonTop":["Urinary Tract Infection","Bacteriuria","Dysuria","Back Pain","Urinary Retention"]}}}